Bristol-Myers Squibb has entered into a strategic partnership with Microsoft to integrate the latter’s advanced imaging technology—currently deployed in approximately 80% of U.S. hospitals—into an AI-enabled workflow for earlier and more precise lung cancer diagnosis. Under the agreement, Bristol-Myers Squibb will leverage its expertise in oncology and drug delivery to develop machine-learning algorithms that analyze radiological images in real time, flagging potential malignancies and streamlining the path to biopsy and treatment. The collaboration aims to reduce diagnostic delays by up to 30% in initial clinical trials and could be expanded to additional tumor types if early performance metrics—such as sensitivity and specificity improvements of 10–15%—are met.

In a deal valued at up to $850 million, Bristol-Myers Squibb has secured exclusive rights to co-develop and commercialize Janux Therapeutics’ TRACTr™ cell-based platform for solid tumor indications. Bristol-Myers Squibb will provide an upfront payment of $125 million, with potential regulatory and commercial milestone payments totaling $725 million, plus tiered royalties on net sales. The partnership targets several high-unmet-need cancers, including non-small cell lung cancer and colorectal carcinoma. Preclinical data presented at a recent oncology conference showed a greater than 70% tumor reduction in murine xenograft models and supported an Investigational New Drug application submission planned for Q4 2026.

Bristol-Myers Squibb’s cardiovascular unit delivered an 89% year-over-year revenue increase for Camzyos in the last fiscal quarter, driven by strong uptake in adult hypertrophic cardiomyopathy markets. Phase 3 SCOUT-HCM trial data demonstrated statistical significance on primary and key secondary endpoints, paving the way for potential label expansion into adolescent oHCM patients by mid-2027. Beyond Camzyos, the company’s oncology pipeline features eight late-stage assets, with three Phase 3 readouts expected over the next 12 months. Combined, these programs represent potential peak annual sales exceeding $10 billion, reinforcing Bristol-Myers Squibb’s growth trajectory in both immuno-oncology and cardiovascular disease.